[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
April 27, 2005

Arthritis Medications and Cardiovascular Events

Author Affiliations
 

Letters Section Editor: Robert M. Golub, MD, Senior Editor.

JAMA. 2005;293(16):1975-1977. doi:10.1001/jama.293.16.1975-b

To the Editor: The Editorial by Dr Topol on the cardiovascular effects of coxibs1 provides new evidence of the ongoing state of confusion involving patients, physicians, and health authorities. The available scientific data, far from clarifying the matter, add to the confusion. An example is the premature cessation of the Alzheimer Disease Anti-inflammatory Prevention Trial (ADAPT) due to an excess of cardiovascular events in the patients treated with naproxen, a nonselective nonsteroidal anti-inflammatory drug (NSAID) previously associated with a reduction in the risk of myocardial infarction.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×